Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study

Brain

Volumn 119, Issue 4, 1996, Pages 1055-1066

  Hahn, A F ^a,g   Bolton, C F ^a   Pillay, N ^b   Chalk, C ^c   Benstead, T ^d   Bril, V ^e   Shumak, K ^e   Vandervoort, M K ^a   Feasby, T E ^f  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Chronic demyelinating polyneuropathy; Conduction block; Double blind trial; Plasma exchange; Prednisone

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMYELINATING NEUROPATHY; DOUBLE BLIND PROCEDURE; FEMALE; GRIP STRENGTH; GUILLAIN BARRE SYNDROME; HUMAN; LATENT PERIOD; MALE; MOTOR NERVE CONDUCTION; MOTOR PERFORMANCE; NERVE BIOPSY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROLOGIC EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

EID: 0029766172     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.4.1055     Document Type: Article

References (54)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). [Review]. Neurology 1991; 41: 617-8.
2. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46: 878-84.
3. Branda RF, Moldow CF, McCullough JJ, Jacob HS. Plasma exchange in the treatment of immune disease. Transfusion 1975; 15: 570-6.
4. Bromberg MB, Feldman EL, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy. Neurology 1992; 42: 1157-63.
5. Buffaloe GW, Dau PC, Erickson RR, Fosburg MT, Grossman L, Taft EG. Technical considerations. In: Dau PC, Cardella CJ, Taft EG, editors. Therapeutic plasma exchange disease compendium. Lakewood (CO): COBE Laboratories, 1983: 3-12.
6. Connolly AM, Pestronk A, Trotter JL, Feldman EL, Cornblath DR, Olney RK. High-titer selective serum anti-β-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology 1993; 43: 557-62.
7. Cornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991; 30: 104-6.
8. Donofrio PD, Tandan R, Albers JW. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1985; 8: 321-7.
9. Dwyer JM. Manipulating the immune system with immune globulin. [Review]. N Engl J Med 1992; 326: 107-16.
10. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621-37.
11. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-41.
12. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314: 461-5.
13. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance [see comments]. N Engl J Med 1991; 325: 1482-6. Comment in: N Engl J Med 1992; 326: 1089-91.
14. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ 3rd. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992; 42: 1164-70.
15. Dyck PJ, Giannini C, Lais A. Pathologic alterations of nerves. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, editors. Peripheral neuropathy. 3rd ed. Philadelphia: W. B. Saunders, 1993a: 514-95.
16. Dyck PJ, Prineas J, Pollard J. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low A, Poduslo JF, editors. Peripheral Neuropathy. 3rd ed. Philadelphia: W. B. Saunders, 1993b: 1498-517.
17. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838-45.
18. Feasby TE, Brown WF, Gilbert JJ, Hahn AF. The pathological basis of conduction block in human neuropathies. J Neurol Neurosurg Psychiatry 1985; 48: 239-44.
19. Fredman P, Vedeler CA, Nyland H, Aarli JA, Svennerholm L. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. J Neurol 1991; 238: 75-9.
20. Gibbels E, Toyka KV, Borberg H, Haupt WF, Hann P. Plasmaaustauschbehandlung bei chronischen Polyneuritiden vom Typ Guillain-Barré. Erfahrungen mit neun eigenen Fällen. Nervenarzt 1986; 57: 129-39.
21. Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance [see comments]. Ann Neurol 1991; 30: 54-61. Comment in: Ann Neurol 1992; 31: 689-91.
22. Gross MLP, Thomas PK. The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J Neurol Sci 1981; 52: 69-78.
23. Hahn AF, Chang Y, Webster HD. Development of myelinated nerve fibers in the sixth cranial nerve of the rat: a quantitative electron microscope study. J Comp Neurol 1987; 260: 491-500.
24. Hahn AF, Kirk H, Jeun R. Nerve biopsy findings in chronic inflammatory demyelinating polyneuropathy [abstract]. Can J Neurol Sci 1996; 23(Suppl 1): S53.
25. Hartung H-P, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome Part I. [Review], Muscle Nerve 1995; 18: 137-53.
26. Heininger K, Liebert UG, Toyka KV, Haneveld FT, Schwendemann G, Kolb-Bachofen V, et al. Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G. J Neurol Sci 1984; 66: 1-14.
27. Heininger K, Gibbels K, Besinger UA, Borberg H, Hartung H-P, Grabensee B, et al. Role of therapeutic plasmapheresis in chronic inflammatory demyelinating polyneuropathy. In: Rock G, editor. Apheresis. New York: Wiley-Liss, 1990: 275-81.
28. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy [see comments]. Arch Neurol 1992; 49: 612-6. comment in: Arch Neurol 1994; 51: 234-6.
29. Ilyas AA, Mithen FA, Dalakas MC, Chen ZW, Cook SD. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1992; 107: 111-21.
30. Julien J, Vital C, Vallat JM, Lagueny A, Ferrer X, Leboutet MJ. Chronic demyelinating neuropathy with IgM-producing lymphocytes in peripheral nerve and delayed appearance of 'benign' monoclonal gammopathy. Neurology 1984; 34: 1387-9.
31. Khalili-Shirazi A, Hughes RAC, Brostoff SW, Linington C, Gregson N. T cell responses to myelin proteins in Guillain-Barré syndrome. J Neurol Sci 1992; 111: 200-3.
32. Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RAC. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 46: 245-51.
33. Koski CL, Humphrey R, Shin ML. Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component I fixation. Proc Natl Acad Sci USA 1985; 82: 905-9.
34. Levy RL, Newkirk R, Ochoa J. Treating chronic relapsing Guillain-Barré syndrome by plasma exchange [letter]. Lancet 1979; 2: 259-60.
35. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. J Hand Surg [Am] 1984; 9: 222-6.
36. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110: 1617-30.
37. NIH Consensus. The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986; 256: 1333-7.
38. Pollard JD. A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies. [Review]. Muscle Nerve 1987; 10: 214-21.
39. Pollard JD, McLeod JG, Gatenby P, Kronenberg H. Prediction of response to plasma exchange in chronic relapsing polyneuropathy. J Neurol Sci 1983; 58: 269-87.
40. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976; 27: 427-58.
41. Rudnicki S, Vriesendorp F, Koski CL, Mayer RF. Electrophysiologic studies in the Guillain-Barré syndrome: effects of plasma exchange and antibody rebound. Muscle Nerve 1992; 15: 57-62.
42. Saida T, Saida K, Lisak RP, Brown MJ, Silberberg DH, Asbury AK. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann Neurol 1982; 11: 69-75.
43. SAS® Institute. SAS®/STAT user's guide: version 6. 4th ed. Cary (NC): SAS® Institute, 1990.
44. Server AC, Lefkowith J, Braine H, McKhann GM. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979; 6: 258-61.
45. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993; 43: 2202-9.
46. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995; 118: 359-68.
47. Simone IL, Annunziata P, Maimone D, Liguori M, Leante R, Livrea P. Serum and CSF anti-GM1 antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1993; 114: 49-55.
48. Sladky JT, Brown MJ, Berman PH. Chronic inflammatory demyelinating polyneuropathy of infancy: a corticosteroid-responsive disorder. Ann Neurol 1986; 20: 76-81.
49. Thornton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. [Review]. Ann Neurol 1994; 35: 260-8.
50. Toyka KV, Augspach R, Wiethölter H, Besinger UA, Haneveld F, Liebert UG, et al. Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic humoral factor. Muscle Nerve 1982; 5: 479-84.
51. Valldeoriola F, Graus F, Steck AJ, Muñoz E, de la Fuente M, Gallart T, et al. Delayed appearance of anti-myelin-associated glycoprotein antibodies in a patient with chronic demyelinating polyneuropathy. Ann Neurol 1993; 34: 394-6.
52. van Doom PA, Brand A, Vermeulen M. Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology 1987; 37: 1798-802.
53. van Nunen SA, Gatenby PA, Pollard JD, Deacon M, Clancy RL. Specificity of plasmapheresis in the treatment of chronic relapsing polyneuropathy. Aust N Z J Med 1982; 12: 81-4.
54. Vermeulen M, van Doom PA, Brand A, Strengers PFW, Jennekens FGJ, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36-9.